OSI 754

Drug Profile

OSI 754

Alternative Names: CP 609754; LNK-754

Latest Information Update: 16 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OSI Pharmaceuticals
  • Developer AstraZeneca; OSI Pharmaceuticals
  • Class Antineoplastics; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Alzheimer's disease; Neurodegenerative disorders
  • Discontinued Bladder cancer

Most Recent Events

  • 12 Jul 2012 OSI 754 licensed to AstraZeneca worldwide
  • 14 Mar 2011 Link Medicine Corporation completes a Phase-I clinical trial in mild Alzheimer's disease in USA (NCT01013610)
  • 09 Jun 2010 OSI Pharmaceuticals has been acquired by Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top